Drugs with this side effect
- 5-ASA: postmarketing
- 5-FU
- 5-aminolevulinic acid
- 5-aza-2'-deoxycytidine: 8.08%
- 5-azacytidine: 1.09% - 5%
- 8-MOP
- CAS 76095-16-4
- CGP 19835A: common
- DFMO: 1.8% - 3.3%
- Enfuvirtide: 4.3% - 5%
- FdUrd
- Glat copolymer: infrequent
- Goserelin
- Insulin
- K779: 1% - 24%
- L-Dmp: infrequent
- Leuprorelin
- MDV3100: 0% - 3.5%
- Metrodin
- NTBC
- Nafarelin
- Octreotide
- Optison
- Photofrin II: common
- SOM230: 6.1% - 6.25%
- SU5416
- Signifor: 6.1% - 6.25%
- Supremon: 1.79%
- Tadenan: 0.4%
- Westcort: 2%
- acamprosate: infrequent
- acitretin: postmarketing
- adapalene: very common, 0.322% - 14%
- afatinib: very common, 0% - 31%
- alendronate: postmarketing
- amlodipine
- amlodipine besylate
- ammonium lactate
- amphotericin B
- anagrelide
- anthracycline
- aripiprazole
- arsenic
- arsenic trioxide
- atazanavir
- atorvastatin
- atropine
- axitinib: 0% - 11%
- azelaic acid: 1% - 9%
- bendamustine: 0%
- betamethasone dipropionate
- bexarotene: 9.43% - 11%
- bicalutamide: postmarketing, rare, 4%
- bimatoprost
- boceprevir: very common, 8% - 18%
- bortezomib
- bosentan
- brimonidine
- buprenorphine
- bupropion: postmarketing, infrequent, 2%
- buspirone: infrequent
- cabazitaxel
- cabozantinib: 0% - 19%
- caffeine: 2.17%
- calcipotriol
- capecitabine
- cefpodoxime
- celecoxib
- cetirizine
- cevimeline
- ciclopirox
- cidofovir
- cilostazol
- ciprofloxacin
- citalopram: infrequent, uncommon
- clindamycin: 0% - 12%
- clindamycin phosphate
- clobetasol: 1%
- clobetasol propionate
- clofarabine: common
- clomipramine: 2%
- colestimide: uncommon
- copolymer 1
- cortisol: 2%
- cyproterone
- dabrafenib: common, 0% - 18%
- darifenacin
- darunavir
- dasatinib
- delavirdine
- deprenyl: infrequent
- dexamethasone
- diclofenac: postmarketing, 0% - 41.9%
- docetaxel: 0% - 6%
- donepezil: infrequent
- doxazosin
- doxorubicin: common, 5.5% - 5.9%
- eletriptan: rare
- eribulin
- erlotinib: 0% - 21%
- eslicarbazepine acetate
- estazolam: rare
- estradiol: postmarketing
- estramustine: 0% - 2%
- estramustine phosphate
- etravirine
- everolimus: common, 0% - 13%
- famotidine
- fesoterodine
- fluconazole
- fluocinonide: postmarketing
- fluoxetine
- flurbiprofen
- fluticasone: 7%
- fluvoxamine: rare, infrequent
- formoterol
- fosinopril
- gabapentin: infrequent
- gadolinium
- gadoversetamide
- ganciclovir
- gatifloxacin
- gefitinib: very common, 0% - 29.2%
- gliclazide
- glycopyrrolate
- halobetasol
- histamine
- hydrochlorothiazide
- icodextrin
- imatinib: common, 0% - 6.7%
- indinavir: 16.2%
- insulin detemir
- iodixanol
- ivermectin
- ketoconazole: postmarketing
- lamotrigine: infrequent, 0% - 2%
- lansoprazole
- lapatinib: very common, 0% - 6%
- lasofoxifene: rare
- leflunomide: postmarketing, common, 0% - 3%
- lenalidomide: postmarketing, very common, 9.35% - 10.1%
- letrozole: uncommon
- leuprorelin acetate
- levonorgestrel
- lomitapide
- losartan
- medroxyprogesterone: postmarketing
- medroxyprogesterone acetate: postmarketing
- melatonin
- memantine
- metolazone
- metronidazole: 1.08% - 2%
- mexiletine
- midodrine
- milnacipran
- mirtazapine: infrequent
- moclobemide
- modafinil
- mometasone furoate
- morphine
- moxifloxacin
- mupirocin
- nadolol
- naproxen
- naratriptan: rare
- nefazodone: infrequent
- niacin: postmarketing
- nilotinib: common, 0% - 10%
- nilutamide
- nisoldipine
- ofloxacin
- olanzapine: infrequent
- olopatadine
- omeprazole: postmarketing
- orlistat: 2.1%
- oxaliplatin
- oxybutynin: 1.8% - 3%
- oxycodone
- paclitaxel: very common
- paliperidone
- pantoprazole
- paroxetine: infrequent, uncommon
- pazopanib
- pentamidine
- pentostatin
- pergolide: infrequent
- perindopril
- perindopril erbumine
- phenyllactate
- pilocarpine
- pirfenidone
- podophyllotoxin: postmarketing
- pomalidomide: 9.35% - 10.7%
- ponatinib: 0% - 39%
- posaconazole
- pramipexole
- pravastatin
- pregabalin: infrequent
- propafenone
- pyridostigmine: 2%
- quetiapine
- rabeprazole: rare
- raltegravir
- regorafenib
- retinoic acid: postmarketing, common, very common, 1.64% - 24-65%
- ribavirin: common, very common, 11% - 23%
- rifapentine
- risperidone: 0% - 4%
- ritonavir
- rivastigmine: infrequent
- ropinirole
- salmon calcitonin acetate
- saquinavir: common
- scopolamine
- sertaconazole
- sertraline: infrequent, frequent
- sibutramine
- sitaxsentan
- sofosbuvir: common
- solifenacin
- sorafenib: postmarketing, 0% - 11%
- sparfloxacin
- spinosad
- stavudine
- sunitinib
- tacrolimus: 0% - 7%
- tazarotene: 3% - 16%
- telmisartan
- temozolomide: common, 0% - 4.91%
- temsirolimus
- testosterone: postmarketing, 1.85% - 1.9%
- testosterone undecanoate
- thalidomide: 0% - 20.6%
- tiagabine: frequent
- tiaprofenic acid
- tiotropium
- tizanidine: infrequent
- tobramycin: uncommon
- tolterodine: 1.7%
- tramadol: postmarketing, uncommon
- trametinib: 0% - 18%
- trandolapril
- trihexyphenidyl
- trospium chloride
- v 1784: postmarketing
- valdecoxib
- valganciclovir
- valproate
- vandetanib: 0% - 15.2%
- varenicline: infrequent
- vemurafenib: postmarketing, 0% - 19%
- venlafaxine: infrequent
- vinflunine
- voriconazole
- zalcitabine
- zaleplon: infrequent
- zonisamide: infrequent
- zopiclone: infrequent
|
Drugs with this indication
|
